Pharvaris PHVS
NASDAQ PHVS
$35.25 -0.41 (-1.15%)
As of: Sep 4, 2026 · 3:59 PM EDT

Pharvaris (PHVS) Change in Receivables (2020 - 2026)

Pharvaris' (PHVS) quarterly Change in Receivables came in at -$335027.6 in Q1 2026, down 154.22% YoY from $617925.2 in Q1 2025, and up 26.04% on a QoQ basis from -$453000.3 in Q4 2025.

Analysis

Pharvaris (PHVS) Change in Receivables (2020 - 2026) Analysis & Trends

Pharvaris (PHVS) has 7 years of Change in Receivables data on file, last reported at -$335027.6 in Q1 2026.

  • Quarterly Change in Receivables fell 154.22% year-over-year to -$335027.6 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$575873.1 (down 141.79% YoY) and the FY2025 annual result came in at -$374350.5, down 907.9% from the prior year.
  • Change in Receivables climbed to -$335027.6 in Q1 2026, from -$453000.3 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $52.5 billion in Q2 2023 to a low of -$52.4 billion in Q3 2023.
  • A 5-year average of $919811.0 and a median of -$12465.8 in 2023 frame the typical range for Change in Receivables.
  • The widest YoY moves for Change in Receivables: up 14582576.89% in 2023, down 72003334.17% in 2023.
  • Tracing PHVS's Change in Receivables over 5 years: stood at $22127.1 in 2022, then plunged by 657.61% to -$123382.3 in 2023, then jumped by 262.44% to $200423.6 in 2024, then sank by 326.02% to -$453000.3 in 2025, then increased by 26.04% to -$335027.6 in 2026.
  • The last three Change in Receivables figures came in at -$335027.6 (Q1 2026), -$453000.3 (Q4 2025), and $153880.4 (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 140.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 838.50 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -53.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 117.58 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 31.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 37.16 Mn
10 Pharvaris 2.10 Bn 1.73 Bn 85,072.10 -82,183.63
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -82,183.63
Mar 31, 2026 -335,027.60
Dec 31, 2025 -453,000.34
Sep 30, 2025 153,880.38
Jun 30, 2025 58,274.42
Mar 31, 2025 -131,787.45
Dec 31, 2024 200,423.62
Sep 30, 2024 100.80 Bn
Jun 30, 2024 -98.84 Bn
Mar 31, 2024 65,667.31
Dec 31, 2023 -123,382.33
Sep 30, 2023 -52.44 Bn
Jun 30, 2023 52.45 Bn
Mar 31, 2023 -12,465.79
Dec 31, 2022 22,127.12
Sep 30, 2022 -371.20 Bn
Jun 30, 2022 392.84 Bn
Mar 31, 2022 34,865.42
Dec 31, 2021 -77,460.56
Sep 30, 2021 94,812.34